ישראל -
עברית -
Ministry of Health
וילאט 1000
dover medical & scientific equipment ltd, israel - factor viii (human); von willebrand factor - אבקה וממס להכנת תמיסה להזרקה - von willebrand factor 1000 iu/vial; factor viii (human) 1000 iu/vial - coagulation factor viii
ישראל -
עברית -
Ministry of Health
וילאט 500
dover medical & scientific equipment ltd, israel - factor viii (human); von willebrand factor - אבקה וממס להכנת תמיסה להזרקה - von willebrand factor 500 iu/vial; factor viii (human) 500 iu/vial - coagulation factor viii
ישראל -
עברית -
Ministry of Health
פאפאוורין טבע להזרקה
teva israel ltd - papaverine hydrochloride - תמיסה להזרקה - papaverine hydrochloride 40 mg / 2 ml - papaverine - papaverine - antispasmodic in visceral spasm, e.g. gastrointestinal colic, biliary and urinary tract spasms. peripheral vascular disease with vasospastic element. vascular spasm associated with acute myocardial infarcion, angina pectoris, peripheral and pulmonary embolism.
ישראל -
עברית -
Ministry of Health
אטרופין טבע 20 מג10 מל
teva israel ltd - atropine sulfate - תמיסה להזרקה - atropine sulfate 20 mg / 10 ml - atropine - atropine - relaxation of spastic situations of the gastrointestinal tract such as pylorospasm, relaxation of biliary and genitourinary tracts, reduction of salivation and bronchial secretion. atropine is used to combat cns and peripheral toxic effects and to suppress vagally-mediated bradyarrhythmias.
ישראל -
עברית -
Ministry of Health
אטרופין טבע 1 מגמל
teva israel ltd - atropine sulfate - תמיסה להזרקה - atropine sulfate 1 mg/ml - atropine - atropine - relaxation of spastic situations of the gastrointestinal tract such as pylorospasm, relaxation of biliary and genitourinary tracts, reduction of salivation and bronchial secretion. atropine is used to combat cns and peripheral toxic effects and to suppress vagally-mediated bradyarrhythmias.
ישראל -
עברית -
Ministry of Health
ביידוריון 2 מג
astrazeneca (israel) ltd - exenatide - אבקה וממס להכנת תרחיף להזרקה - exenatide 2 mg - exenatide - exenatide - bydureon is indicated for treatment of type 2 diabetes mellitus in combination with : • metformin• sulphonylurea• metformin and sulphonylureain adults who have not achieved adequate glycaemic control on maximally tolerated doses of these oral therapies.
ישראל -
עברית -
Ministry of Health
ויקטוזה
novo nordisk ltd., israel - liraglutide - תמיסה להזרקה - liraglutide 6.0 mg/ml - liraglutide - liraglutide - for the treatment of adults with type 2 diabetes mellitus to achieve glycemic control : in combination with : - metformin or a sulphonylurea, in patients with insufficient glycemic control despite maximal tolerated dose of monotherapy with mentformin or sulphonylurea. - metformin and sulphonylurea or metformin and a thiazolidinedione in patients with insufficient glycemic control despite dual therapy.
ישראל -
עברית -
Ministry of Health
פלויקס 75 מג
sanofi israel ltd - clopidogrel as hydrogen sulfate - טבליות מצופות פילם - clopidogrel as hydrogen sulfate 75 mg - clopidogrel - clopidogrel - prevention of atherotrobmotic eventsclopidogrel is indicated in :• adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.• adult patients suffering from acute coronary syndrome- non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave myocardial infarction (mi)), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapyprevention of atherotrobmotic and thromboembolic events in atrial fibrillation: in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for the treatment with vitamin k antagonists (vka) anti-thrombin or anti factor xa, and who have a low bleeding risk, clopid